Cite
HARVARD Citation
van den Elsen, S. et al. (2020). Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid. European respiratory journal. 56 (4), p. . [Online].